CovidChloroV1, Main, Exploration, bibRecord, 001270

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Identifieur interne : 001270 ( Main/Exploration ); précédent : 001269; suivant : 001271

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Auteurs : G. Solé [France] ; E. Salort-Campana [France] ; Y. Pereon [France] ; T. Stojkovic [France] ; K. Wahbi [France] ; P. Cintas [France] ; D. Adams [France] ; P. Laforet [France] ; V. Tiffreau [France] ; I. Desguerre [France] ; L I Pisella [France] ; A. Molon [France] ; S. Attarian [France]

Source :

Revue neurologique [ 0035-3787 ] ; 2020.

RBID : pubmed:32354651

Descripteurs français

English descriptors

Abstract

In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.

DOI: 10.1016/j.neurol.2020.04.004
PubMed: 32354651
PubMed Central: PMC7167585

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001825
to stream Main, to step Curation: 001825

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.</title>
<author><name sortKey="Sole, G" sort="Sole, G" uniqKey="Sole G" first="G" last="Solé">G. Solé</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center for Neuromuscular Disorders AOC, Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center for Neuromuscular Disorders AOC, Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Salort Campana, E" sort="Salort Campana, E" uniqKey="Salort Campana E" first="E" last="Salort-Campana">E. Salort-Campana</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pereon, Y" sort="Pereon, Y" uniqKey="Pereon Y" first="Y" last="Pereon">Y. Pereon</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU Nantes, Reference Center for Neuromuscular Disorders AOC, Hôtel-Dieu, Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU Nantes, Reference Center for Neuromuscular Disorders AOC, Hôtel-Dieu, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stojkovic, T" sort="Stojkovic, T" uniqKey="Stojkovic T" first="T" last="Stojkovic">T. Stojkovic</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wahbi, K" sort="Wahbi, K" uniqKey="Wahbi K" first="K" last="Wahbi">K. Wahbi</name>
<affiliation wicri:level="3"><nlm:affiliation>AP-HP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Île-de-France, Paris-Descartes, Sorbonne Paris Cité University, 75006 Paris, France; INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP-HP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Île-de-France, Paris-Descartes, Sorbonne Paris Cité University, 75006 Paris, France; INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cintas, P" sort="Cintas, P" uniqKey="Cintas P" first="P" last="Cintas">P. Cintas</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders AOC, Toulouse, University Hospitals, 31000 Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders AOC, Toulouse, University Hospitals, 31000 Toulouse</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Adams, D" sort="Adams, D" uniqKey="Adams D" first="D" last="Adams">D. Adams</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, CHU Bicetre, Hôpitaux Universitaires Paris Sud, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology, CHU Bicetre, Hôpitaux Universitaires Paris Sud, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laforet, P" sort="Laforet, P" uniqKey="Laforet P" first="P" last="Laforet">P. Laforet</name>
<affiliation wicri:level="1"><nlm:affiliation>Nord/Est/Île-de-France Neuromuscular Reference Center, Neurology Department, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France; INSERM U1179, END-ICAP, Versailles-Saint-Quentin-en-Yvelines University, Université Paris Saclay, Montigny-le-Bretonneux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nord/Est/Île-de-France Neuromuscular Reference Center, Neurology Department, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France; INSERM U1179, END-ICAP, Versailles-Saint-Quentin-en-Yvelines University, Université Paris Saclay, Montigny-le-Bretonneux</wicri:regionArea>
<wicri:noRegion>Montigny-le-Bretonneux</wicri:noRegion>
<wicri:noRegion>Montigny-le-Bretonneux</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tiffreau, V" sort="Tiffreau, V" uniqKey="Tiffreau V" first="V" last="Tiffreau">V. Tiffreau</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Hôpital Pierre-Swynghedauw, CHU de Lille, EA 7369 URePSSS, 59000 Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Hôpital Pierre-Swynghedauw, CHU de Lille, EA 7369 URePSSS, 59000 Lille</wicri:regionArea>
<placeName><region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Desguerre, I" sort="Desguerre, I" uniqKey="Desguerre I" first="I" last="Desguerre">I. Desguerre</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pisella, L I" sort="Pisella, L I" uniqKey="Pisella L" first="L I" last="Pisella">L I Pisella</name>
<affiliation wicri:level="3"><nlm:affiliation>Filnemus, AP-HM, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Filnemus, AP-HM, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molon, A" sort="Molon, A" uniqKey="Molon A" first="A" last="Molon">A. Molon</name>
<affiliation wicri:level="3"><nlm:affiliation>Filnemus, AP-HM, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Filnemus, AP-HM, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Attarian, S" sort="Attarian, S" uniqKey="Attarian S" first="S" last="Attarian">S. Attarian</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France. Electronic address: Shahram.ATTARIAN@ap-hm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32354651</idno>
<idno type="pmid">32354651</idno>
<idno type="doi">10.1016/j.neurol.2020.04.004</idno>
<idno type="pmc">PMC7167585</idno>
<idno type="wicri:Area/Main/Corpus">001825</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001825</idno>
<idno type="wicri:Area/Main/Curation">001825</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001825</idno>
<idno type="wicri:Area/Main/Exploration">001825</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.</title>
<author><name sortKey="Sole, G" sort="Sole, G" uniqKey="Sole G" first="G" last="Solé">G. Solé</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center for Neuromuscular Disorders AOC, Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center for Neuromuscular Disorders AOC, Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Salort Campana, E" sort="Salort Campana, E" uniqKey="Salort Campana E" first="E" last="Salort-Campana">E. Salort-Campana</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pereon, Y" sort="Pereon, Y" uniqKey="Pereon Y" first="Y" last="Pereon">Y. Pereon</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU Nantes, Reference Center for Neuromuscular Disorders AOC, Hôtel-Dieu, Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU Nantes, Reference Center for Neuromuscular Disorders AOC, Hôtel-Dieu, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stojkovic, T" sort="Stojkovic, T" uniqKey="Stojkovic T" first="T" last="Stojkovic">T. Stojkovic</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wahbi, K" sort="Wahbi, K" uniqKey="Wahbi K" first="K" last="Wahbi">K. Wahbi</name>
<affiliation wicri:level="3"><nlm:affiliation>AP-HP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Île-de-France, Paris-Descartes, Sorbonne Paris Cité University, 75006 Paris, France; INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP-HP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Île-de-France, Paris-Descartes, Sorbonne Paris Cité University, 75006 Paris, France; INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cintas, P" sort="Cintas, P" uniqKey="Cintas P" first="P" last="Cintas">P. Cintas</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders AOC, Toulouse, University Hospitals, 31000 Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders AOC, Toulouse, University Hospitals, 31000 Toulouse</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Adams, D" sort="Adams, D" uniqKey="Adams D" first="D" last="Adams">D. Adams</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, CHU Bicetre, Hôpitaux Universitaires Paris Sud, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology, CHU Bicetre, Hôpitaux Universitaires Paris Sud, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laforet, P" sort="Laforet, P" uniqKey="Laforet P" first="P" last="Laforet">P. Laforet</name>
<affiliation wicri:level="1"><nlm:affiliation>Nord/Est/Île-de-France Neuromuscular Reference Center, Neurology Department, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France; INSERM U1179, END-ICAP, Versailles-Saint-Quentin-en-Yvelines University, Université Paris Saclay, Montigny-le-Bretonneux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nord/Est/Île-de-France Neuromuscular Reference Center, Neurology Department, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France; INSERM U1179, END-ICAP, Versailles-Saint-Quentin-en-Yvelines University, Université Paris Saclay, Montigny-le-Bretonneux</wicri:regionArea>
<wicri:noRegion>Montigny-le-Bretonneux</wicri:noRegion>
<wicri:noRegion>Montigny-le-Bretonneux</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tiffreau, V" sort="Tiffreau, V" uniqKey="Tiffreau V" first="V" last="Tiffreau">V. Tiffreau</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Hôpital Pierre-Swynghedauw, CHU de Lille, EA 7369 URePSSS, 59000 Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Hôpital Pierre-Swynghedauw, CHU de Lille, EA 7369 URePSSS, 59000 Lille</wicri:regionArea>
<placeName><region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Desguerre, I" sort="Desguerre, I" uniqKey="Desguerre I" first="I" last="Desguerre">I. Desguerre</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pisella, L I" sort="Pisella, L I" uniqKey="Pisella L" first="L I" last="Pisella">L I Pisella</name>
<affiliation wicri:level="3"><nlm:affiliation>Filnemus, AP-HM, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Filnemus, AP-HM, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molon, A" sort="Molon, A" uniqKey="Molon A" first="A" last="Molon">A. Molon</name>
<affiliation wicri:level="3"><nlm:affiliation>Filnemus, AP-HM, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Filnemus, AP-HM, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Attarian, S" sort="Attarian, S" uniqKey="Attarian S" first="S" last="Attarian">S. Attarian</name>
<affiliation wicri:level="3"><nlm:affiliation>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France. Electronic address: Shahram.ATTARIAN@ap-hm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (therapeutic use)</term>
<term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Cardiorespiratory Fitness (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Emergency Treatment (MeSH)</term>
<term>France (epidemiology)</term>
<term>Glycogen Storage Disease Type II (therapy)</term>
<term>Hospitalization (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immune System Diseases (therapy)</term>
<term>Immunoglobulins, Intravenous (therapeutic use)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Muscular Atrophy, Spinal (drug therapy)</term>
<term>Neuromuscular Diseases (therapy)</term>
<term>Oligonucleotides (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Physical Therapy Modalities (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Prognosis (MeSH)</term>
<term>RNA, Small Interfering (therapeutic use)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Steroids (therapeutic use)</term>
<term>Withholding Treatment (MeSH)</term>
<term>alpha-Glucosidases (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Abstention thérapeutique (MeSH)</term>
<term>Amyotrophie spinale (traitement médicamenteux)</term>
<term>Antagonistes des récepteurs aux angiotensines (usage thérapeutique)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Azithromycine (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Capacité cardiorespiratoire (MeSH)</term>
<term>France (épidémiologie)</term>
<term>Glycogénose de type II (thérapie)</term>
<term>Hospitalisation (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Immunoglobulines par voie veineuse (usage thérapeutique)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term>
<term>Maladies du système immunitaire (thérapie)</term>
<term>Maladies neuromusculaires (thérapie)</term>
<term>Oligonucléotides (usage thérapeutique)</term>
<term>Pandémies (MeSH)</term>
<term>Petit ARN interférent (usage thérapeutique)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Pronostic (MeSH)</term>
<term>Stéroïdes (usage thérapeutique)</term>
<term>Techniques de physiothérapie (MeSH)</term>
<term>Traitement d'urgence (MeSH)</term>
<term>alpha-Glucosidase (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term>
<term>Angiotensin-Converting Enzyme Inhibitors</term>
<term>Anti-Bacterial Agents</term>
<term>Antimalarials</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulins, Intravenous</term>
<term>Immunosuppressive Agents</term>
<term>Oligonucleotides</term>
<term>RNA, Small Interfering</term>
<term>Steroids</term>
<term>alpha-Glucosidases</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Muscular Atrophy, Spinal</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Glycogen Storage Disease Type II</term>
<term>Immune System Diseases</term>
<term>Neuromuscular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Glycogénose de type II</term>
<term>Maladies du système immunitaire</term>
<term>Maladies neuromusculaires</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Amyotrophie spinale</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term>
<term>Antibactériens</term>
<term>Antipaludiques</term>
<term>Azithromycine</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulines par voie veineuse</term>
<term>Immunosuppresseurs</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term>
<term>Oligonucléotides</term>
<term>Petit ARN interférent</term>
<term>Stéroïdes</term>
<term>alpha-Glucosidase</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>France</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Cardiorespiratory Fitness</term>
<term>Emergency Treatment</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Physical Therapy Modalities</term>
<term>Prognosis</term>
<term>SARS-CoV-2</term>
<term>Withholding Treatment</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Abstention thérapeutique</term>
<term>Betacoronavirus</term>
<term>Capacité cardiorespiratoire</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Pronostic</term>
<term>Techniques de physiothérapie</term>
<term>Traitement d'urgence</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32354651</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>176</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.</ArticleTitle>
<Pagination><MedlinePgn>507-515</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0035-3787(20)30523-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2020.04.004</ELocationID>
<Abstract><AbstractText>In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Solé</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Reference Center for Neuromuscular Disorders AOC, Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Salort-Campana</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pereon</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>CHU Nantes, Reference Center for Neuromuscular Disorders AOC, Hôtel-Dieu, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stojkovic</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wahbi</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>AP-HP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Île-de-France, Paris-Descartes, Sorbonne Paris Cité University, 75006 Paris, France; INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cintas</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Reference Center of Neuromuscular Disorders AOC, Toulouse, University Hospitals, 31000 Toulouse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Adams</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, CHU Bicetre, Hôpitaux Universitaires Paris Sud, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laforet</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Nord/Est/Île-de-France Neuromuscular Reference Center, Neurology Department, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France; INSERM U1179, END-ICAP, Versailles-Saint-Quentin-en-Yvelines University, Université Paris Saclay, Montigny-le-Bretonneux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tiffreau</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Hôpital Pierre-Swynghedauw, CHU de Lille, EA 7369 URePSSS, 59000 Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Desguerre</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pisella</LastName>
<ForeName>L I</ForeName>
<Initials>LI</Initials>
<AffiliationInfo><Affiliation>Filnemus, AP-HM, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molon</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Filnemus, AP-HM, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Attarian</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France; Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France. Electronic address: Shahram.ATTARIAN@ap-hm.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>FILNEMUS COVID-19 study group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017065">Practice Guideline</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>50FKX8CB2Y</RegistryNumber>
<NameOfSubstance UI="C000606954">patisiran</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5Z9SP3X666</RegistryNumber>
<NameOfSubstance UI="C000590926">nusinersen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.20</RegistryNumber>
<NameOfSubstance UI="C509951">GAA protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.20</RegistryNumber>
<NameOfSubstance UI="D000520">alpha-Glucosidases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072599" MajorTopicYN="N">Cardiorespiratory Fitness</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004638" MajorTopicYN="N">Emergency Treatment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006009" MajorTopicYN="N">Glycogen Storage Disease Type II</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007154" MajorTopicYN="N">Immune System Diseases</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009134" MajorTopicYN="N">Muscular Atrophy, Spinal</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009468" MajorTopicYN="N">Neuromuscular Diseases</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D026741" MajorTopicYN="N">Physical Therapy Modalities</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D028761" MajorTopicYN="N">Withholding Treatment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000520" MajorTopicYN="N">alpha-Glucosidases</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Guidelines</Keyword>
<Keyword MajorTopicYN="N">Management</Keyword>
<Keyword MajorTopicYN="N">Neuromuscular</Keyword>
<Keyword MajorTopicYN="N">Treatment</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32354651</ArticleId>
<ArticleId IdType="pii">S0035-3787(20)30523-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.neurol.2020.04.004</ArticleId>
<ArticleId IdType="pmc">PMC7167585</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA Intern Med. 2018 Jun 1;178(6):745-746</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29710200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Neurol. 2015 Mar;72(3):349-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25580942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2005 Aug 30;173(5):489-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16129869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2017 Dec 17;388(10063):3017-3026</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27939059</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Muscle Nerve. 2019 Dec;60(6):693-699</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31469909</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105633</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol Neurosurg Psychiatry. 1994 Jul;57(7):778-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8021660</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 2014 Jul;350(1):46-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24784568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 May;79(5):667-668</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32241793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurology. 2015 Mar 31;84(13):1369-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25825463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 19;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):1653-1659</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol. 2018 Dec;265(12):2783-2788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30232608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neuromuscul Dis. 2016 Nov 29;3(4):517-527</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27911335</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Explor. 2019 Dec 06;1(12):e0066</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32166247</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Muscle Nerve. 2020 Jan;61(1):17-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31531874</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105954</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32234467</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol. 2012 Jul;259(7):1290-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22160434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2018 Jul;142(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29925575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Mar 13;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Reumatismo. 2015 Dec 30;67(3):849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26876193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2015 May;43(5):973-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25668751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2019 Apr 11;53(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30705129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol Sci. 2019 Nov 15;406:116428</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31574325</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Orphanet J Rare Dis. 2015 Sep 04;10:109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26338094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2018 Jul 5;379(1):11-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29972753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol. 2014 Sep;261(9):1684-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24923245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol Sci. 2020 May 15;412:116803</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32247193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2019 Dec 6;12:CD003907</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31808555</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2018 Oct;142(Suppl 2):S82-S89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30275252</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Aquitaine</li>
<li>Hauts-de-France</li>
<li>Midi-Pyrénées</li>
<li>Nord-Pas-de-Calais</li>
<li>Nouvelle-Aquitaine</li>
<li>Occitanie (région administrative)</li>
<li>Pays de la Loire</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Île-de-France</li>
</region>
<settlement><li>Bordeaux</li>
<li>Lille</li>
<li>Marseille</li>
<li>Nantes</li>
<li>Paris</li>
<li>Toulouse</li>
</settlement>
</list>
<tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Sole, G" sort="Sole, G" uniqKey="Sole G" first="G" last="Solé">G. Solé</name>
</region>
<name sortKey="Adams, D" sort="Adams, D" uniqKey="Adams D" first="D" last="Adams">D. Adams</name>
<name sortKey="Attarian, S" sort="Attarian, S" uniqKey="Attarian S" first="S" last="Attarian">S. Attarian</name>
<name sortKey="Cintas, P" sort="Cintas, P" uniqKey="Cintas P" first="P" last="Cintas">P. Cintas</name>
<name sortKey="Desguerre, I" sort="Desguerre, I" uniqKey="Desguerre I" first="I" last="Desguerre">I. Desguerre</name>
<name sortKey="Laforet, P" sort="Laforet, P" uniqKey="Laforet P" first="P" last="Laforet">P. Laforet</name>
<name sortKey="Molon, A" sort="Molon, A" uniqKey="Molon A" first="A" last="Molon">A. Molon</name>
<name sortKey="Pereon, Y" sort="Pereon, Y" uniqKey="Pereon Y" first="Y" last="Pereon">Y. Pereon</name>
<name sortKey="Pisella, L I" sort="Pisella, L I" uniqKey="Pisella L" first="L I" last="Pisella">L I Pisella</name>
<name sortKey="Salort Campana, E" sort="Salort Campana, E" uniqKey="Salort Campana E" first="E" last="Salort-Campana">E. Salort-Campana</name>
<name sortKey="Stojkovic, T" sort="Stojkovic, T" uniqKey="Stojkovic T" first="T" last="Stojkovic">T. Stojkovic</name>
<name sortKey="Tiffreau, V" sort="Tiffreau, V" uniqKey="Tiffreau V" first="V" last="Tiffreau">V. Tiffreau</name>
<name sortKey="Wahbi, K" sort="Wahbi, K" uniqKey="Wahbi K" first="K" last="Wahbi">K. Wahbi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001270 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001270 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32354651
   |texte=   Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32354651" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki